News
Sarepta stands behind Elevidys after FDA requests gene therapy be pulled from market
As the controversy over the safety of Sarepta Therapeutics’ gene therapies comes to a head, the biotech is standing firm behind its approved Duchenne muscular dystrophy (DMD) treatment. | As the controversy over the safety of Sarepta Therapeutics’ gene therapies comes to a head,
Sarepta shares rebound after shipments of gene therapy Elevidys resume in US
Sarepta Therapeutics shares surged more than 30% before the bell on Tuesday, as analysts said the resumption of U.S. shipments for its muscular gene therapy partially removes financial headwinds and decreases the risk of market withdrawal.
Wall Street analysts were quick to downgrade Sarepta Therapeutics (NASDAQ:SRPT) on Monday as the company suspended its revenue guidance for 2025 following a second fatality linked to Elevidys, its ...
Sarepta management is predicting a significant uptick in use in the near future. Up until June, Elevidys was only available to certain boys with Duchenne who were 4 or 5 years old, capping its ...
Teenager who received Elevidys, Sarepta’s Duchenne gene therapy, dies By Jason Mast STAT,Updated March 18, 2025, 2:50 p.m.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback